Operating Segments

3 Months Ended

Mar. 31, 2017

Operating Segments [Abstract]

Operating Segments

Note 10. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended  March 31,
	2017			2016
Revenues
Vaccines/BioDefense	$	1,330,884		$	2,630,986
BioTherapeutics		-			-
Total	$	1,330,884		$	2,630,986
Income/(Loss) from Operations
Vaccines/BioDefense	$	136,600		$	317,991
BioTherapeutics		(1,027,555	)		(1,245,585	)
Corporate		(847,235	)		(978,111	)
Total	$	(1,738,190	)	$	(1,905,705	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	9,769		$	10,019
BioTherapeutics		9,567			10,433
Corporate		1,714			2,155
Total	$	21,050		$	22,607
Interest Income (Expense), Net
Corporate	$	4,753		$	(3,885	)
Share-Based Compensation
Vaccines/BioDefense	$	17,998		$	28,006
BioTherapeutics		49,770			34,832
Corporate		78,859			73,573
Total	$	146,627		$	136,411

	As of  March 31, 2017		As of December 31, 2016
Identifiable Assets
Vaccines/BioDefense	$	1,073,536	$	1,297,986
BioTherapeutics		43,320		49,422
Corporate		7,292,354		8,919,698
Total	$	8,409,210	$	10,267,105